BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting

BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonstrated durable effects in platinum-resistant ovarian cancer. The company is advancing over 25 Phase 2 and 3 trials, aiming to deliver innovative cancer treatments through monotherapies and novel combinations. These presentations highlight BioNTech's commitment to developing diverse therapies addressing high unmet medical needs in cancer.